Cell Signaling Technology

Product Pathways - Cell Cycle / Checkpoint

SignalSilence® RBL2 siRNA I #14712

No. Size Price
14712S 300 µl ( 3 nmol ) ¥3,224.00 现货查询 购买询价
14712 carrier free & custom formulation / quantityemail request
Applications Dilution Species-Reactivity Sensitivity MW (kDa) Isotype
TFN Human,

Species cross-reactivity is determined by western blot.

Applications Key: TFN=Transfection,

Description

SignalSilence® RBL2 siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit RBL2 expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.

Quality Control

Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.

Western Blotting

Western Blotting

Western blot analysis of extracts from 293 cells, transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-) or SignalSilence® RBL2 siRNA I (+), using RBL2 (D9T7M) Rabbit mAb #13610 (upper) and α-Actinin (D6F6) XP® Rabbit mAb #6487 (lower). The RBL2 (D9T7M) Rabbit mAb confirms silencing of RBL2 expression, while the α-Actinin (D6F6) XP® Rabbit mAb is used as a loading control.

Directions for Use

CST recommends transfection with 100 nM SignalSilence® RBL2 siRNA I 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.

Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.

Background

The retinoblastoma (Rb) tumor suppressor family includes the retinoblastoma protein Rb (p105), retinoblastoma-like protein 1 (RBL1, p107), and retinoblastoma-like protein 2 (RBL2, p130). These Rb family proteins are referred to as ‘pocket proteins’ because they contain a conserved binding pocket region that interacts with critical regulatory proteins, including E2F family transcription factors, c-Abl tyrosine kinase, and proteins containing a conserved LXCXE motif (1,2). In quiescent G0 phase cells, active Rb proteins are hypophosphorylated and bind to E2F transcription factors to repress transcription and inhibit cell cycle progression (1,2). Upon growth factor induction of quiescent cells, Rb proteins become hyperphosphorylated and inactivated by G1-phase cyclinD-cdk4/6, G1/S-phase cyclin E-cdk2, and G1/S-phase cyclin A-cdk2 complexes (1,2). Hyperphosphorylation of Rb proteins results in a loss of E2F binding and allows for transcriptional activation and cell cycle progression (1,2). In addition to regulating the cell cycle, Rb proteins regulate chromosome stability, induction, and maintenance of senescence, apoptosis, cellular differentiation, and angiogenesis (3).

Retinoblastoma-like protein 2 (RBL2, p130) is the most predominant and active Rb family member found in quiescent cells. In these cells, RBL2 interacts with E2F4 and E2F5 to recruit the DP, RB-like, E2F, and MuvB protein (DREAM) complex to E2F target genes to repress transcription of multiple genes required for progression into S phase and mitosis (4-6). Hypophosphorylation of RBL2 during cellular senescence is required for maintenance of senescent cells (7,8).

  1. Du, W. and Pogoriler, J. (2006) Oncogene 25, 5190-200.
  2. Giacinti, C. and Giordano, A. (2006) Oncogene 25, 5220-7.
  3. Indovina, P. et al. (2013) J Cell Physiol 228, 525-35.
  4. Moberg, K. et al. (1996) Mol Cell Biol 16, 1436-49.
  5. Takahashi, Y. et al. (2000) Genes Dev 14, 804-16.
  6. Smith, E.J. et al. (1996) Mol Cell Biol 16, 6965-76.
  7. Kapić, A. et al. (2006) Cell Death Differ 13, 324-34.
  8. Helmbold, H. et al. (2009) Oncogene 28, 3456-67.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Protocols

Companion Products


For Research Use Only. Not For Use In Diagnostic Procedures.

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

XP is a registered trademark of Cell Signaling Technology, Inc.

SignalSilence is a registered trademark of Cell Signaling Technology, Inc.

Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.

用户评论 --- 共 0

该产品暂无评论!

我要参与评论 :

如要参与评论请先登录网站

还没有网站账户?去注册一下吧

Products

 

Applications